News

As part of the agreement, Catalent will provide vial filling and packaging capacity, as well as additional staffing required for 24×7 manufacturing operations at the site to support

Compared with glycopyrronium/formoterol fumarate, PT010 achieved a 24% reduction (p<0.001) in exacerbations. PT010 achieved a 13% reduction (p=0.003) compared with PT009 (budesonide/formoterol fumarate). The dual-combination therapies used as

Under the agreement, Symbiosis will provide AstraZeneca fast-track access to sterile vaccine drug product manufacturing capacity for clinical trial supply. The agreement follows AstraZeneca’s recent announcement of a

RLF-100 is a synthetic form of human vasoactive intestinal peptide (VIP), which minimises inflammation in the lungs and protects the alveolar type II cells that are considered to

The randomized, double-blind, placebo-controlled, multi-center study will have the primary objective of demonstrating the superiority of NRD135S.E1 over placebo in relieving PDPN in patients after 3 months of

The French vaccines company, which is part of Sanofi, signed a collaboration and license agreement deal worth up to $805m with Translate Bio in 2018 for developing mRNA

Frontier Scientific identified and developed multiple synthetic processes to produce stannous protoporphyrin (SnPP) – the active pharmaceutical ingredient of RBT-9, an investigational drug entering a Phase 2 trial

The deal also provides Gilead with an exclusive option to acquire the remaining stake in Pionyr for around $315m. The shareholders of Pionyr will secure up to an

The QINLOCK New Drug Submission was approved by Health Canada under Project Orbis, an initiative of the U.S. Food and Drug Administration’s (FDA) Oncology Center of Excellence designed